Rice Hall James & Associates’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-770,711
| Closed | -$11.1M | – | 246 |
|
|
2026
Q1 | $11.1M | Sell |
770,711
-2,738,860
| -78% | -$39.3M | 0.62% | 52 |
|
|
2025
Q4 | $50M | Buy |
3,509,571
+74,854
| +2% | +$735K | 2.75% | 3 |
|
|
2025
Q3 | $27.1M | Buy |
3,434,717
+674,403
| +24% | +$4.8M | 1.48% | 19 |
|
|
2025
Q2 | $15.8M | Buy |
2,760,314
+750,210
| +37% | +$4.84M | 0.85% | 35 |
|
|
2025
Q1 | $16.4M | Buy |
2,010,104
+639,024
| +47% | +$5.91M | 0.96% | 30 |
|
|
2024
Q4 | $12.9M | Buy |
1,371,080
+398,942
| +41% | +$4.15M | 0.71% | 39 |
|
|
2024
Q3 | $10.4M | Sell |
972,138
-146
| -0% | -$1.59K | 0.56% | 51 |
|
|
2024
Q2 | $9.65M | Sell |
972,284
-56,285
| -5% | -$578K | 0.58% | 51 |
|
|
2024
Q1 | $12.1M | Sell |
1,028,569
-37,396
| -4% | -$478K | 0.69% | 42 |
|
|
2023
Q4 | $15.1M | Sell |
1,065,965
-12,900
| -1% | -$146K | 0.88% | 36 |
|
|
2023
Q3 | $13.1M | Buy |
1,078,865
+30,202
| +3% | +$390K | 0.83% | 38 |
|
|
2023
Q2 | $13.2M | Buy |
1,048,663
+201,804
| +24% | +$2.39M | 0.75% | 41 |
|
|
2023
Q1 | $9.39M | Buy |
846,859
+138,971
| +20% | +$1.71M | 0.53% | 50 |
|
|
2022
Q4 | $8.64M | Sell |
707,888
-6,521
| -0.9% | -$73.4K | 0.5% | 54 |
|
|
2022
Q3 | $7.46M | Sell |
714,409
-199,866
| -22% | -$2.23M | 0.43% | 61 |
|
|
2022
Q2 | $9.82M | Buy |
914,275
+284,658
| +45% | +$2.34M | 0.47% | 57 |
|
|
2022
Q1 | $5.96M | Buy |
629,617
+14,420
| +2% | +$135K | 0.24% | 85 |
|
|
2021
Q4 | $7.11M | Sell |
615,197
-31,701
| -5% | -$353K | 0.25% | 81 |
|
|
2021
Q3 | $6.18M | Sell |
646,898
-3,722
| -0.6% | -$38.1K | 0.23% | 84 |
|
|
2021
Q2 | $6.27M | Sell |
650,620
-140,747
| -18% | -$1.37M | 0.22% | 81 |
|
|
2021
Q1 | $7.82M | Buy |
791,367
+198,835
| +34% | +$3.08M | 0.25% | 79 |
|
|
2020
Q4 | $13.7M | Buy |
+592,532
| New | +$12.1M | 0.48% | 56 |
|
Other funds holding FOLD
Rice Hall James & Associates's FOLD Position: Q2 2026 in Review
Rice Hall James & Associates sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 770,711 shares — an estimated $11.1M sold.
Rice Hall James & Associates first reported a position in FOLD in Q4 2020 and held it in 22 quarters. The position peaked at $50M in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Rice Hall James & Associates reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Rice Hall James & Associates sold 770,711 Amicus Therapeutics shares in Q2 2026, an estimated $11.1M.
- Rice Hall James & Associates first reported a position in Amicus Therapeutics in Q4 2020 and held it in 22 quarters.
- Rice Hall James & Associates's Amicus Therapeutics position peaked at $50M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.